- Global Pharma News & Resources

Biosimilar Hormones Global Market Report 2022: Prevalence of Hormonal Deficiencies Driving Demand and Boosting Growth -

DUBLIN--(BUSINESS WIRE)--The "Biosimilar Hormones Global Market Report 2022: By Type, By Application, By Distribution" report has been added to's offering.

The global biosimilar hormones market is expected to grow from $1.74 billion in 2021 to $2.31 billion in 2022 at a compound annual growth rate (CAGR) of 32.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.22 billion in 2026 at a CAGR of 28.1%.

The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones. These hormones are used when patients have a drop in hormones in their bodies or are unbalanced. Only goods and services traded between entities or sold to end consumers are included.

The main types of biosimilar hormones are teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars and others. Teriparatide is a parathyroid hormone recombinant (PTH). Teriparatide is similar to a component of human PTH, and when taken on a regular basis, it stimulates osteoblasts more than osteoclasts, resulting in an increase in bone mass. The different applications include research and biotechnology, diagnostics, biocatalysts, therapeutics, others and distributed through various channels such as hospital and retail pharmacy, online pharmacy or e-pharmacy, speciality clinics.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market.

For instance, according to the Italian Journal of Pediatrics, the prevalence of growth hormone deficiency (GHD) in childhood widely varies between 1 out of 3480 and 1 out of 30,000 children annually. In children, the growth hormone can influence bone mineralization and lead to several metabolic effects, including glucose and lipid homeostasis. Annually, about 6,000 adults are diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market.

Stringent regulations imposed on the approval of hormone biosimilars limits the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market.

Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launch in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products across various locations to boost sales and maximize profits. For instance, in October 2019, Biocon Biologics and Mylan N.V. announced the launch of biosimilar hormones in Australia to treat the polygenic disorder.


Markets Covered:

1) By Type: Teriparatide Biosimilars; Follitropin Alfa Biosimilars; Insulin Biosimilars; Somatropin Biosimilars; Others

2) By Application: Research & Biotechnology; Diagnostics; Biocatalysts; Therapeutics; Others

3) By Distribution Channel: Hospital And Retail Pharmacy; Online Pharmacy/epharmacy; Speciality Clinics

Key Topics Covered:

1. Executive Summary

2. Biosimilar Hormones Market Characteristics

3. Biosimilar Hormones Market Trends And Strategies

4. Impact Of COVID-19 On Biosimilar Hormones

5. Biosimilar Hormones Market Size And Growth

6. Biosimilar Hormones Market Segmentation

7. Biosimilar Hormones Market Regional And Country Analysis

8. Asia-Pacific Biosimilar Hormones Market

9. China Biosimilar Hormones Market

10. India Biosimilar Hormones Market

11. Japan Biosimilar Hormones Market

12. Australia Biosimilar Hormones Market

13. Indonesia Biosimilar Hormones Market

14. South Korea Biosimilar Hormones Market

15. Western Europe Biosimilar Hormones Market

16. UK Biosimilar Hormones Market

17. Germany Biosimilar Hormones Market

18. France Biosimilar Hormones Market

19. Eastern Europe Biosimilar Hormones Market

20. Russia Biosimilar Hormones Market

21. North America Biosimilar Hormones Market

22. USA Biosimilar Hormones Market

23. South America Biosimilar Hormones Market

24. Brazil Biosimilar Hormones Market

25. Middle East Biosimilar Hormones Market

26. Africa Biosimilar Hormones Market

27. Biosimilar Hormones Market Competitive Landscape And Company Profiles

28. Biosimilar Hormones Pipeline Analysis

29. Key Mergers And Acquisitions In The Biosimilar Hormones Market

30. Biosimilar Hormones Market Future Outlook and Potential Analysis

31. Appendix

Companies Mentioned

  • Teva Pharmaceutical
  • Gedeon Richter
  • Intas Pharmaceuticals
  • Biocon
  • Mylan
  • Sanofi
  • Sandoz (Novartis)
  • LG Life Sciences
  • Ferring Pharmaceuticals
  • GC Pharma

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Nov-2022